Korro Bio, Inc. Restricted Cash and Cash Equivalents, Noncurrent
Korro Bio, Inc. (KRRO) had Restricted Cash and Cash Equivalents, Noncurrent of $1.00 million as of 2025-12-31, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent › Restricted Cash and Cash Equivalent, Noncurrent
us-gaap:RestrictedCashAndCashEquivalentsNoncurrent · last filed 2026-08-06
- 2025-12-31: Restricted Cash and Cash Equivalents, Noncurrent $1.00M.
| Period end | Restricted Cash and Cash Equivalents, Noncurrent |
|---|---|
| 2025-12-31 | $1.00M 10-Q · filed 2026-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |